KIK-AS Phase 1/2 Trial of GTX-102 Can Resume Enrollment in Canada

KIK-AS Phase 1/2 Trial of GTX-102 Can Resume Enrollment in Canada

295536

KIK-AS Phase 1/2 Trial of GTX-102 Can Resume Enrollment in Canada

Health Canada has given the green light for a Phase 1/2 clinical trial to resume enrollment to test the investigational therapy GTX-102 in children and adolescents with Angelman syndrome in Canada. This follows an amendment to the trial’s protocol, submitted by GeneTx Biotherapeutics and Ultragenyx Pharmaceutical, the therapy co-developers, after the study was placed on hold due to five patients in the U.S. experiencing serious, but reversible, muscle weakness in their legs and feet after being treated with the…

You must be logged in to read/download the full post.